Evans, C
09/529882

- key terms

```
     FILE 'REGISTRY' ENTERED AT 12:38:49 ON 29 NOV 2000
                E GATIFLOXACIN/CN 5
L1             1 SEA ABB=ON  PLU=ON  GATIFLOXACIN/CN
                E DISODIUM EDETATE/CN 5
L2             1 SEA ABB=ON  PLU=ON  "DISODIUM EDETATE"/CN

     FILE 'CAPLUS' ENTERED AT 12:39:40 ON 29 NOV 2000
L3           253 SEA ABB=ON  PLU=ON  L1 OR GATIFLOXACIN
L4             0 SEA ABB=ON  PLU=ON  L3 AND (L2 OR (DISODIUM OR DI(W)(NA
                OR SODIUM))(W)EDETATE)

     FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
     JICST-EPLUS, JAPIO' ENTERED AT 12:41:09 ON 29 NOV 2000
L5             0 SEA ABB=ON  PLU=ON  L4

     FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
     JICST-EPLUS, JAPIO' ENTERED AT 12:42:16 ON 29 NOV 2000
L6            43 SEA ABB=ON  PLU=ON  YASUEDA S?/AU
L7          3670 SEA ABB=ON  PLU=ON  INADA K?/AU
L8             7 SEA ABB=ON  PLU=ON  L6 AND L7
L9          3706 SEA ABB=ON  PLU=ON  L6 OR L7
L10            2 SEA ABB=ON  PLU=ON  L9 AND L3
L11            7 SEA ABB=ON  PLU=ON  L8 OR L10
L12            5 DUP REM L11 (2 DUPLICATES REMOVED)
```

- author (s)

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 1

ACCESSION NUMBER: 2000:144737 CAPLUS
DOCUMENT NUMBER: 132:185458
TITLE: Aqueous liquid preparations of **gatifloxacin**
INVENTOR(S): **Yasueda, Shinichi; Inada, Katsuhiro**
PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan; Kyorin Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010570	A1	20000302	WO 1999-JP4483	19990820

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA,

Searcher : Shears 308-4994

ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9953026	A1	20000314	AU 1999-53026	19990820
EP 1025846	A1	20000809	EP 1999-938550	19990820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9906735	A	20000815	BR 1999-6735	19990820
PRIORITY APPLN. INFO.:			JP 1998-235432	19980821
			WO 1999-JP4483	19990820

AB This invention relates to aq. prepns. contg. **gatifloxacin** [(.+-.)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-quinolinecarboxylic acid] or its salts and sodium edetate. Also disclosed are a method for enhancing the corneal permeability of **gatifloxacin**, a method for preventing crystn. of **gatifloxacin** and a method for preventing coloration of **gatifloxacin** each by blending **gatifloxacin** or its salt with sodium edetate. An aq. soln. for eye drops, ear drops, and nasal drops, contained **gatifloxacin** 0.5, Na edetate 0.1, NaCl 0.9, HCl/NaOH q.s. to pH 7, and sterilized water to 100 mL.

REFERENCE COUNT: 12
REFERENCE(S):
(1) Anon; GB 2199745 A
(2) Anon; EP 230295 A2 CAPLUS
(9) Kubo, S; Chemotherapy 1994, V40(5), P333 CAPLUS
(11) Sasaki, H; Pharmaceutical Research 1995, V12(8), P1146 CAPLUS
(12) Tanaka; Antimicrobial Agents and Chemotherapy 1995, V39(10), P2367 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 5 JAPIO COPYRIGHT 2000 JPO
ACCESSION NUMBER: 1999-029483 JAPIO
TITLE: COMPOSITION CONTAINING DIFLUPREDNATE
INVENTOR: KIMURA KIYOKO; **YASUEDA SHINICHI**; YAMAGUCHI MASAZUMI; **INADA KATSUHIRO**
PATENT ASSIGNEE(S): SENJU PHARMACEUT CO LTD, JP (CO 402938)
MITSUBISHI CHEM CORP, JP (CO 000596)
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 11029483	A	19990202	Heisei (6)	A61K031-575

JP
APPLICATION INFORMATION
ST19N FORMAT: JP1998-129908 19980513
Searcher : Shears 308-4994

ORIGINAL: JP10129908 Heisei
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 99, No. 2
AN 1999-029483 JAPIO
AB PURPOSE: TO BE SOLVED:To obtain the subject composition good in transferability to a diseased part, homogeneous in drug distribution, hardly causing a sense of incompatibility and foreign body sensation, and capable of preventing and treating inflammatory disease and allergic disease by including difluprednate, an oil, water and an emulsifier.
CONSTITUTION: composition contains difluprednate, an oil containing a fatty acid ester of glycerol, water and an emulsifier containing a surfactant. The formulation amounts of the components are 10-100,000 pts.wt. oil, 100-100,000 pts.wt. water and 10-100,000 pts.wt. emulsifier based on 1 pt.wt. difluprednate. Especially, the weight ratio of the oil to the water, which is a medium, is preferably (1:4) to (1:99). The composition is prepared to form an aqueous preparation such as oil-in-water type emulsion. The administration in low doses sufficiently manifests drug action, and thereby the side effect is reduced and the composition is readily administered to a topical portion such as an eye, a nose and an ear.

L12 ANSWER 3 OF 5 JAPIO COPYRIGHT 2000 JPO
ACCESSION NUMBER: 1999-029463 JAPIO
TITLE: AQUEOUS SUSPENSION AGENT HAVING GOOD RE-DISPERSIBILITY
INVENTOR: **YASUEDA SHINICHI**; MATSUHISA KEIICHI; TERAYAMA HIDEO; **INADA KATSUHIRO**
PATENT ASSIGNEE(S): SENJU PHARMACEUT CO LTD, JP (CO 402938)
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 11029463	A	19990202	Heisei	(6) A61K009-107

JP
APPLICATION INFORMATION
ST19N FORMAT: JP1998-127510 19980511
ORIGINAL: JP10127510 Heisei
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 99, No. 2
AN 1999-029463 JAPIO
AB PURPOSE: TO BE SOLVED:To obtain a stable aqueous suspension agent having good re- dispersibility when a slightly soluble medicine is prepared in injection, eye drop, nasal drop, oral agent, lotion, etc.
CONSTITUTION: aqueous suspension agent capable of readily re-dispersing and not causing aggregation or caking of disperse particles can be prepared by formulating an aqueous liquid agent of

a slightly soluble medicine with a water-soluble polymer in the range from a concentration which starts to lower surface tension of liquid agent to a concentration at which lowering of surface tension is stopped. The aqueous suspension agent is useful for injections, eye drops, nasal drops, oral agents, lotions, etc., because of good redispersibility.

L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 2
ACCESSION NUMBER: 1998:761804 CAPLUS
DOCUMENT NUMBER: 130:7437
TITLE: Aqueous suspensions with excellent redispersibility
INVENTOR(S): **Yasueda, Shin-ichi**; Matsuhisa, Keiichi; Terayama, Hideo; **Inada, Katsuhiro**
PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851281	A1	19981119	WO 1998-JP1998	19980430
W: CA, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 995435	A1	20000426	EP 1998-917756	19980430
R: BE, CH, DE, ES, FR, GB, IT, LI				
JP 11029463	A2	19990202	JP 1998-127510	19980511
PRIORITY APPLN. INFO.:			JP 1997-124166	19970514
			WO 1998-JP1998	19980430

AB An aq. suspension comprises hardly sol. drugs and water-sol. polymers at a concn. within a range from the concn. at which the decrease in the surface tension of the liq. prepns. is initiated to the concn. at which such decrease is terminated. These prepns. can be easily redispersed and undergo neither aggregation of the dispersed particles nor caking. The excellent redispersibility of these prepns. makes them useful as injections, eye drops, nasal drops, drugs for internal use, lotions, etc. An ophthalmic suspension contained fluorometholone 0.1, Me cellulose 0.0006, NaCl 0.85, Na2HPO4.cntdot.12H2O 0.1, benzalkonium chlorides 0.005 g, 0.1 N HCl q.s. to pH 7, and distd. water to 100 mL.

REFERENCE COUNT: 5
REFERENCE(S):
(1) Anon; EP 531529 A1
(2) Anon; US 5366985 A
(3) Anon; WO 9217174 A1 CAPLUS

Searcher : Shears 308-4994

(4) Nippon Kayaku Co, Ltd; JP 52-96721 A 1977
(5) Takeda Chemical Industries, Ltd; JP 05-186348 A 1993

L12 ANSWER 5 OF 5 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1998-585485 [50] WPIDS
DOC. NO. CPI: C1998-175294
TITLE: Liquid di flupredate composition comprising an oil, water and emulsifier - used to treat inflammatory and allergic diseases e.g. allergic conjunctivitis, vernal conjunctivitis and blepharitis marginalis.
DERWENT CLASS: A96 B01
INVENTOR(S): **INADA, K**; KIMURA, M; YAMAGUCHI, M; **YASUEDA, S**; KATSUHIRO, I; MASAKO, K; MASAZUMI, Y; SHIN-ICHI, Y
PATENT ASSIGNEE(S): (MITU) MITSUBISHI CHEM CORP; (SENP) SENJU PHARM CO LTD; (SENP) SENJU SEIYAKU KK
COUNTRY COUNT: 30
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 878197	A1	19981118	(199850)*	EN	12
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
JP 11029483	A	19990202	(199915)		8
CA 2237503	A	19981114	(199917)		
CN 1200926	A	19981209	(199917)		
KR 98087017	A	19981205	(200009)		
US 6114319	A	20000905	(200044)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 878197	A1	EP 1998-108611	19980512
JP 11029483	A	JP 1998-129908	19980513
CA 2237503	A	CA 1998-2237503	19980513
CN 1200926	A	CN 1998-109772	19980514
KR 98087017	A	KR 1998-17258	19980513
US 6114319	A	US 1998-76124	19980512

PRIORITY APPLN. INFO: JP 1997-124415 19970514
AN 1998-585485 [50] WPIDS
AB EP 878197 A UPAB: 19981217
A difluprednate liquid composition comprises difluprednate, oil, water and an emulsifier.

Searcher : Shears 308-4994

USE - Difluprednate has antiinflammatory and antiallergic activity and is used to treat inflammatory and allergic diseases e.g. allergic conjunctivitis, vernal conjunctivitis, blepharitis marginalis, acatarrhal conjunctivitis and uveitis.

ADVANTAGE - The composition allows uniform drug distribution and superior transfer of difluprednate into a lesion and is associated with less uncomfortable feeling and foreign sensation.

Dwg.0/0

FILE 'CAPLUS' ENTERED AT 12:44:28 ON 29 NOV 2000

L13 1 SEA ABB=ON PLU=ON L3 AND ((EYE OR EAR OR NOSE OR NASAL OR OCULAR)(3A)DROP)

L14 3 SEA ABB=ON PLU=ON L3(S)(AQUEOUS OR AQ)

L15 3 SEA ABB=ON PLU=ON L13 OR L14

L15 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 2000:144737 CAPLUS

DOCUMENT NUMBER: 132:185458

TITLE: **Aqueous** liquid preparations of **gatifloxacin**

INVENTOR(S): Yasueda, Shinichi; Inada, Katsuhiro

PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan; Kyorin Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010570	A1	20000302	WO 1999-JP4483	19990820
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9953026	A1	20000314	AU 1999-53026	19990820
EP 1025846	A1	20000809	EP 1999-938550	19990820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9906735	A	20000815	BR 1999-6735	19990820
PRIORITY APPLN. INFO.:			JP 1998-235432	19980821
			WO 1999-JP4483	19990820

Searcher : Shears 308-4994

AB This invention relates to **aq**. prepns. contg. **gatifloxacin** [(.+-.)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-quinolinecarboxylic acid] or its salts and sodium edetate. Also disclosed are a method for enhancing the corneal permeability of **gatifloxacin**, a method for preventing crystn. of **gatifloxacin** and a method for preventing coloration of **gatifloxacin** each by blending **gatifloxacin** or its salt with sodium edetate. An **aq**. soln. for **eye drops**, **ear drops**, and **nasal drops**, contained **gatifloxacin** 0.5, Na edetate 0.1, NaCl 0.9, HCl/NaOH q.s. to pH 7, and sterilized water to 100 mL.

IT **112811-59-3, Gatifloxacin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized **aq**. prepns. contg. **gatifloxacin** and edetate)

REFERENCE COUNT: 12
REFERENCE(S):
(1) Anon; GB 2199745 A
(2) Anon; EP 230295 A2 CAPLUS
(9) Kubo, S; Chemotherapy 1994, V40(5), P333 CAPLUS
(11) Sasaki, H; Pharmaceutical Research 1995, V12(8), P1146 CAPLUS
(12) Tanaka; Antimicrobial Agents and Chemotherapy 1995, V39(10), P2367 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:736482 CAPLUS
DOCUMENT NUMBER: 131:342037
TITLE: Oral medicinal preparations with reproducible release of gatifloxacin or its salts or hydrates
INVENTOR(S): Bartholomaeus, Johannes; Betzing, Juergen
PATENT ASSIGNEE(S): Gruenenthal G.m.b.H., Germany
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958129	A1	19991118	WO 1999-EP2893	19990429

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ZA

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

DE 19820801	A1	19991125	DE 1998-19820801	19980509
AU 9940352	A1	19991129	AU 1999-40352	19990429
PRIORITY APPLN. INFO.:			DE 1998-19820801	19980509
			WO 1999-EP2893	19990429

AB Solid oral medicinal prepns. having a multiphase structure and good bioavailability are provided for oral administration of gatifloxacin or its pharmaceutically suitable salts or hydrates thereof, which also contain additives including fillers, binding agents, lubricants, disintegrating agents, or mixts. thereof. The inner phase contains the active ingredient (gatifloxacin), binding agents, fillers, disintegrating agents, or mixts. thereof; .gtoreq.1 outer phase consists of .gtoreq.1 disintegrating agent as well as other additives selected from .gtoreq.1 lubricant and possibly fillers and/or binding agents. Tablets, granules, pellets, etc. prepd. from these ingredients by granulation show a drug release interval of 6.5-25 min. Thus, 110.47 g microcryst. cellulose and 81 g hydroxypropylcellulose were sieved, mixed with 586.13 g **gatifloxacin** (moisture content 7.87 wt.%), and granulated with 700 mL **aq**. hydroxypropylcellulose soln. for 5 min; the granulate was sieved, dried at 50.degree. for 17 h, sieved, mixed with 16.20 g Mg stearate, and pressed into tablets with a hardness of 140-150 N.

REFERENCE COUNT: 2

REFERENCE(S):
(1) Kyorin, S; EP 0230295 A 1987
(2) Rinaldi, M; US 5436253 A 1995

L15 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1999:654922 CAPLUS

DOCUMENT NUMBER: 131:295090

TITLE: Fundamental and clinical studies of gatifloxacin in ophthalmology

AUTHOR(S): Ooishi, Masao; Tazawa, Yutaka; Fukuda, Atsushi; Suzuki, Akiko; Imai, Akira; Sasaki, Kazuyuki; Kitagawa, Kazuko; Asano, Koichi; Hujiwara, Takaaki; Yoshino, Kei; Suzuki, Mari; Miyanaga, Yoshitaka; Tokuda, Kazuo; Miyao, Yoko; Hara, jiro

CORPORATE SOURCE: Dep. Ophthalmol., Niigata Univ., Sch. Med., 757 Ichiban-cho, Asahimachi-dori, Niigata, 951-8510, Japan

SOURCE: Nippon Kagaku Ryoho Gakkai Zasshi (1999), 47(Suppl. 2, Gatifloxacin), 387-401
CODEN: NKRZE5; ISSN: 1340-7007

PUBLISHER: Nippon Kagaku Ryoho Gakkai

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB Studies of the fundamental characteristics and clin. usefulness of

gatifloxacin, a newly developed fluoroquinolone antibacterial drug, were performed in the field of ophthalmol. The antibacterial activity of gatifloxacin (GFLX) was found to be similar to tosufloxacin (TFLX) and sparfloxacin (SPFX), and superior to ofloxacin (OFLX). MICs of GFLX against std. strains (35 strains) were below concn. (1.71 .mu.g/mL), rising to 200 mg oral administration of GFLX except for a single strain of Pseudomonas aeruginosa. Against Staphylococcus aureus stored in our lab., MIC90 of GFLX was 0.10 .mu.g/mL, a value similar to that of TFLX and SPFX. MIC90 of GFLX was 3.13 .mu.g/mL against Pseudomonas aeruginosa stored in our lab., a level of antibacterial activity between SPFX and TFLX against these strains. After 200 mg oral administration, concns. of GFLX in human aq. humor, tarsus gland tissue, and conjunctiva were 0.04-0.22 .mu.g/mL (at 2.37-24.03 h, 0.09-0.60 times the serum level), 4.36-6.02 .mu.g/g (at 1.87-2.5 h, 2.71-3,17 times the serum level), and 2.27-3.46 .mu.g/g (at 2.00-2.37 h, 1.22-1.48 times the serum level), resp. In a clin. study, GFLX was administered orally once or twice a day at daily doses of 200 mg, 300 mg, or 400 mg to forty-four cases evaluated for clin. efficacy. Clin. response was excellent in 34 cases, good in 7 cases, fair in 2 cases, and poor in 1 case, with an efficacy rate of 93.2% (41/44). As to bacteriol. efficacy, the eradication rate was 92.0% (23/25) for the twenty-five cases evaluated. Side effects were evaluated in 46 cases, and one case of discomfort epigastric was found, an appearance rate of 2.2% (1/46). In the 18 cases evaluated for abnormal lab. findings, there was one case of elevation of LAP, making the appearance rate of abnormal lab. findings 5.6% (1/18). Finally, the usefulness rate was 93.2% (41/44).

(FILE 'CAPLUS' ENTERED AT 12:44:28 ON 29 NOV 2000)

L16 0 SEA ABB=ON PLU=ON GFLX AND ((EYE OR EAR OR NOSE OR NASAL OR OCULAR)(3A)DROP)
L17 1 SEA ABB=ON PLU=ON GFLX(S)(AQUEOUS OR AQ)
L18 0 SEA ABB=ON PLU=ON GFLX AND (L2 OR (DISODIUM OR DI(W)(NA OR SODIUM))(W)EDETATE)
L19 0 SEA ABB=ON PLU=ON (L17 OR L16 OR L18) NOT L15

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO' ENTERED AT 12:48:27 ON 29 NOV 2000)

L20 3 S L15
L21 0 S L16
L22 2 S L17
L23 0 S L18
L24 3 S L20 OR L22
L25 2 DUP REM L24 (1 DUPLICATE REMOVED)

L25 ANSWER 1 OF 2 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2000-282864 [24] WPIDS
DOC. NO. CPI: C2000-085299

TITLE: **Aqueous** liquid preparation comprising **gatifloxacin** which has increased corneal permeability and stability.

DERWENT CLASS: B03

INVENTOR(S): INADA, K; YASUEDA, S

PATENT ASSIGNEE(S): (KYOR) KYORIN PHARM CO LTD; (SENP) SENJU PHARM CO LTD

COUNTRY COUNT: 88

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000010570	A1	20000302	(200024)*	JA	16

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AU 9953026	A	20000314	(200031)		
EP 1025846	A1	20000809	(200039)	EN	

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

BR 9906735	A	20000815	(200045)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000010570	A1	WO 1999-JP4483	19990820
AU 9953026	A	AU 1999-53026	19990820
EP 1025846	A1	EP 1999-938550	19990820
		WO 1999-JP4483	19990820
BR 9906735	A	BR 1999-6735	19990820
		WO 1999-JP4483	19990820

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9953026	A	Based on	WO 200010570
EP 1025846	A1	Based on	WO 200010570
BR 9906735	A	Based on	WO 200010570

PRIORITY APPLN. INFO: JP 1998-235432 19980821

AN 2000-282864 [24] WPIDS

AB WO 200010570 A UPAB: 20000522

NOVELTY - **Aqueous** liquid preparation comprises **gatifloxacin** ((+/-)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-quinolinecarboxylic acid)

or its salt and sodium edetate.

ACTIVITY - Antibacterial; Antiinflammatory; Ophthalmological.

In a corneal permeability test a composition comprising **gatifloxacin** (0.5 g), sodium edetate (0.05 g), sodium chloride (0.9 g) and sterile water (to 100 ml) with a pH 6.0, was administered at 50 micro l to the eyes of white rabbits. The concentration of **gatifloxacin** in the vitreous humor after 1 hour was 1.93 micro g/ml compared to 1.30 micro g/ml for a comparative composition without the sodium edetate.

USE - As **aqueous** liquid preparations for administering **gatifloxacin** directly to the eyes, ears or nose, for treating bacterial infections, inflamed eyelids, styes, swollen tear sac, conjunctivitis, inflamed cornea, corneal edema, external or internal otitis or inflammation of the nasal cavity.

ADVANTAGE - Corneal permeability and solubility of **gatifloxacin** is enhanced, and crystallization and coloration of **gatifloxacin** is prevented.

Dwg.0/0

L25 ANSWER 2 OF 2 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.DUPLICATE 1

ACCESSION NUMBER: 1999360318 EMBASE

TITLE: Fundamental and clinical studies of gatifloxacin in ophthalmology.

AUTHOR: Ooishi M.; Tazawa Y.; Fukuda A.; Suzuki A.; Imai A.; Sasaki K.; Kitagawa K.; Asano K.; Hujiwara T.; Yoshino K.; Suzuki M.; Miyanaga Y.; Tokuda K.; Miyao Y.; Hara J.

CORPORATE SOURCE: M. Ooishi, Department of Ophthalmology, Niigata University, School of Medicine, 757 Ichiban-cho, Asahimachi-dori, Niigata 951-8510, Japan

SOURCE: Japanese Journal of Chemotherapy, (1999) 47/SUPPL. 2 (387-401).
Refs: 19
ISSN: 1340-7007 CODEN: NKRZE5

COUNTRY: Japan

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 012 Ophthalmology
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: Japanese

SUMMARY LANGUAGE: English; Japanese

AB Studies of the fundamental characteristics and clinical usefulness of **gatifloxacin**, a newly developed fluoroquinolone antibacterial drug, were performed in the field of ophthalmology. 1) Antibacterial activity: The antibacterial activity of **gatifloxacin** (**GFLX**) was found to be similar to tosufloxacin (TFLX) and sparfloxacin (SPFX), and superior to ofloxacin (OFLX). MICs of **GFLX** against standard strains

(35 strains) were below concentration (1.71 .mu.g/mL), rising to 200 mg oral administration of **GFLX** except for a single strain of Pseudomonas aeruginosa. Against Staphylococcus aureus stored in our laboratory, MIC90 of **GFLX** was 0.10 .mu.g/mL, a value similar to that of TFLX and SPFX. MIC90 of **GFLX** was 3.13 .mu.g/mL against Pseudomonas aeruginosa stored in our laboratory, a level of antibacterial activity between SPFX and TFLX against these strains. 2) Ocular penetration: After 200 mg oral administration, concentrations of **GFLX** in human **aqueous** humor, tarsus gland tissue, and conjunctiva were 0.04 .apprx. 0.22 .mu.g/mL (at 2.37 .apprx. 24.03 h, 0.09 .apprx. 0.60 times the serum level), 4.36 .apprx. 6.02 .mu.g/g (at 1.87 .apprx. 2.5 h, 2.71 .apprx. 3.17 times the serum level), and 2.27 .apprx. 3.46 .mu.g/g (at 2.00 .apprx. 2.37 h, 1.22 .apprx. 1.48 times the serum level), respectively. 3) Clinical study: In a clinical study, **GFLX** was administered orally once or twice a day at daily doses of 200 mg, 300 mg, or 400 mg to forty-four cases evaluated for clinical efficacy. Clinical response was excellent in 34 cases, good in 7 cases, fair in 2 cases, and poor in 1 case, with an efficacy rate of 93.2% (41/44). As to bacteriological efficacy, the eradication rate was 92.0% (23/25) for the twenty-five cases evaluated. Side effects were evaluated in 46 cases, and one case of discomfort epigastric was found, an appearance rate of 2.2% (1/46). In the 18 cases evaluated for abnormal laboratory findings, there was one case of elevation of LAP, making the appearance rate of abnormal laboratory findings 5.6% (1/18). Finally, the usefulness rate was 93.2% (41/44).

(FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO' ENTERED AT 12:50:08 ON 29 NOV 2000)

L26 0 S L9 AND GFLX

FILE 'HOME' ENTERED AT 12:50:32 ON 29 NOV 2000